Fibrinopeptide A, human TFA is a native N-terminal fibrinogen segment enriched in acidic and aromatic residues. The peptide contributes to studies of fibrin assembly, proteolytic cleavage, and conformational motifs. Researchers employ it in structural mapping, solvent-dependent folding, and kinetic assays. Its trifluoroacetate form supports consistent handling in analytical work.
CAT No: R2218
CAS No:61533-47-9
Synonyms/Alias:FIBRINOPEPTIDE A, HUMAN TFA;61533-47-9;G13977;
Fibrinopeptide A, human tfa is a synthetic peptide corresponding to the amino-terminal sequence of the human fibrinogen Aα chain, which is released during the enzymatic conversion of fibrinogen to fibrin by thrombin. As a well-characterized peptide fragment, it plays a pivotal role in coagulation research and serves as a valuable tool for investigating the molecular mechanisms underlying blood clot formation. Due to its defined sequence and biological relevance, this peptide is widely utilized in studies of proteolytic processing, thrombin specificity, and the regulation of hemostasis, making it a fundamental reagent for both basic and applied biochemical research.
Coagulation pathway analysis: Fibrinopeptide A is extensively employed in the study of the coagulation cascade, particularly for elucidating the precise steps involved in the conversion of fibrinogen to fibrin. Researchers utilize this peptide to monitor thrombin activity, as its release marks a critical event in clot formation. By quantifying the generation of fibrinopeptide fragments, investigators gain insight into the kinetics and regulation of thrombin-catalyzed reactions, facilitating a deeper understanding of hemostatic balance and dysregulation in various pathophysiological conditions.
Protease substrate specificity studies: As a defined substrate, the peptide is instrumental in profiling the specificity and catalytic efficiency of thrombin and related serine proteases. Through in vitro assays using fibrinopeptide A, scientists can characterize enzyme-substrate interactions, determine cleavage preferences, and assess the impact of cofactors or inhibitors on proteolytic activity. Such studies are essential for advancing knowledge of enzyme mechanisms and for the rational design of anticoagulant agents or protease inhibitors.
Mass spectrometry calibration and biomarker validation: The unique sequence of human fibrinopeptide A makes it an ideal internal standard or calibrant in mass spectrometry-based proteomics. Laboratories frequently employ this peptide to optimize instrument performance, validate peptide identification workflows, and ensure quantitative accuracy in complex biological samples. Its use in biomarker validation further supports the reliable detection and quantification of coagulation-related peptides in plasma or serum, contributing to robust analytical protocols.
Antibody production and immunoassay development: The well-defined structure of fibrinopeptide A allows for its use as an immunogen or reference antigen in the generation of sequence-specific antibodies. These antibodies are critical tools for developing immunoassays aimed at detecting fibrinopeptide fragments in biological fluids, supporting research into thrombin activity, coagulation disorders, and related physiological or pathological processes. The availability of high-quality peptide standards enhances assay sensitivity and specificity.
Peptide structure-function relationship investigations: Researchers leverage the synthetic peptide to dissect the structural determinants that govern its recognition and processing by thrombin and other coagulation factors. Through mutagenesis studies and biophysical analyses, the peptide serves as a model system for understanding how sequence variations influence proteolytic cleavage, binding interactions, and downstream signaling. Insights gained from such studies inform the broader field of protein engineering and the development of novel biomolecular tools for coagulation research.
2. Emu oil in combination with other active ingredients for treating skin imperfections
3. High fat diet and GLP-1 drugs induce pancreatic injury in mice
5. Cell-based adhesion assays for isolation of snake venom’s integrin antagonists
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More